US FDA rescinds 510(k) clearance of ReGen's Menaflex
This article was originally published in RAJ Devices
Executive Summary
The US Food and Drug Administration has officially retracted its pre-market notification (510(k)) clearance of ReGen Biologics' Menaflex meniscus implant, forcing the firm to remove it from sale in the US1.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?